aladdin 阿拉丁 P409134 泊马度胺 19171-19-8 10mM in DMSO

中文名：泊马度胺

英文名：Pomalidomide (CC-4047)

英文别名：4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

纯度：10mM in DMSO

货号：P409134

包装：1ml

Cas号：19171-19-8

存储温度：-80℃储存

产品介绍：

Information

Pomalidomide (CC-4047) inhibits LPS-inducedTNF-αrelease withIC50of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targetingE3 ligaseand inhibiting theE3 ligase protein cereblon (CRBN). Pomalidomide promotesapoptosisand cell cycle a
In vitro

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls.

In vivo

Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity.
Cell Data

cell lines：PPC-1 cells

Concentrations：Dissolved in DMSO, final concentrations 2.5-40 μg/mL

Incubation Time：24 or 48 hours

Powder Purity:≥98%

查看阿拉丁官网此产品相关对应页面：https://www.aladdin-e.com/zh_cn/P409134.html